Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug By: Benzinga via Benzinga July 24, 2014 at 06:50 AM EDT Gilead Sciences Inc. (Nasdaq: GILD) beat second-quarter expectations on rapid revenue growth lead by sales of its Sovaldi drug for ... Read More >> Related Stocks: Gilead Sciences